Skip to content

Plant Sterols and Beta-Glucan for Reducing Cardiovascular Disease Risk (Beta-GAPS Trial)

ß-Glucan and Phytosterols for Lipid-Lowering in Hypercholesterolaemic Individuals: A Randomised Controlled Trial (ß-GAPS Trial)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618001455257
Acronym
ß-GAPS Trial
Enrollment
80
Registered
2018-08-29
Start date
2017-09-19
Completion date
2018-07-03
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Cardiovascular disease (CVD) is the leading cause of death worldwide. Dyslipidaemias and insulin resistance have been associated with the development of CVD. In addition, elevated levels of chronic inflammation has also been shown to play a key role in the pathobiology of CVD. Targeting blood lipid levels, insulin sensitivity and chronic inflammation in high risk individuals may help to ameliorate these modifiable risk factors and reduce the overall risk of developing CVD. Phytosterols are well-known cholesterol-lowering agents, resulting in 10% reductions in LDL-C in only 3-4 weeks of supplementation. Oat beta-glucan is a rich source of soluble fibre which has been shown to lower cholesterol levels with implications for glucose control. This project aims to investigate if combined dietary supplementation with plant sterols and beta-glucan reduces blood cholesterol and to a larger extent than either of the treatments alone.It is expected that participants will have improved levels of blood cholesterol as well as an overall reduced 10-year risk of developing CVD.

Interventions

The effects of dietary supplementation with 2g of phytosterols (phytosterol-enriched margarine) with or without 3g oat beta-glucan each day. This randomised control trial is a 2x2 factorial placebo-controlled, double-blinded design. Hypercholesterolaemic individuals will be randomly assigned to one of the following treatment arms for 6 weeks: Arm 1: Placebo-Placebo (PP) Group: 8 small sweet vanilla wholemeal biscuits (no phytosterols, no ß-glucan) per day. Arm 2: ß-Glucan (ßG) Group: 8 sweet van

The effects of dietary supplementation with 2g of phytosterols (phytosterol-enriched margarine) with or without 3g oat beta-glucan each day. This randomised control trial is a 2x2 factorial placebo-controlled, double-blinded design. Hypercholesterolaemic individuals will be randomly assigned to one of the following treatment arms for 6 weeks: Arm 1: Placebo-Placebo (PP) Group: 8 small sweet vanilla wholemeal biscuits (no phytosterols, no ß-glucan) per day. Arm 2: ß-Glucan (ßG) Group: 8 sweet vanilla wholemeal biscuits fortified with oat ß-glucan powder (no phytosterols, 3g oat ß-glucan) per day. Arm 3: Phytosterol (PS) Group: 8 sweet vanilla wholemeal biscuits fortified with Logical margarine (2g phytosterols, no ß-glucan) per day. Arm 4: Phytosterol-ß-Glucan Group (ßG-PS) : 8 sweet vanilla wholemeal biscuits fortified with ß-glucan and Logicol margarine (2g phytosterols, 3g oat ß-glucan) per day. Prior to the trial appointments, participants complete consent form and questionnaires (medical, physical and 3-day food diary) as fast overnight (10hours) avoiding vigorous activity and alcohol 24hours prior. Participants will attend two clinic visits (baseline and post-intervention) at the Nutraceuticals Research Program at the University of Newcastle that will take 30 minutes in which anthropometric, blood pressure, questionnaires and fasted blood sample will be collected by the lead investigator (PhD student and Accredited Practising Dietitian). Participants will be given the option to participate in an optional 2-hour blood glucose test meal component which is only at baseline, following straight after the appointment. This component involves 5 finger prick tests at timepoint 0, 30min, 60min, 90min and 120min. The biscuits will be made prior to the study and packaged/sealed and provided to participants along with instructions on how to consume the biscuits at their initial visit to the research clinic. The biscuits are to be consumed by participants in between meals (i.e. snack times) with fluid and a daily biscuit consumption log kept for the duration of the trial. To assess compliance: 1. Participants will be asked to record their daily consumption of the intervention biscuits in a standardised log provided to them. 2. Participants will be asked to return all unused biscuit bags to the study site when they attend their final appointment at the end of the study period. They will be asked to keep any unfinished and empty biscuits and return them at the end of the study.

Sponsors

University of Newcastle
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Factorial
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age: 18-70 years * Gender: both males and females * Fasting Total cholesterol levels greater than or equal to 5.5mmol/L

Exclusion criteria

* Pregnant or lactating * History of cardiovascular events (e.g. stroke, heart attack, angina, aneurysm, hemorrhage, myocardial infarction etc) * People with pace maker implants * Diabetes mellitus * A chronic inflammatory disease and/or condition (e.g. cancer) * Hypertension * Liver or renal disease * Taking anti-inflammatory medications/supplements (e.g. Aspirin, Atacand, Celebrex) * Taking hypolipidaemic medications/supplements (e.g. Lipitor, Crestor, Zocor) * Taking regular dietary supplements known to influence blood lipid levels (e.g. fish oil, fibre, curcumin) * Already consuming phytosterol-enriched products and/or oat beta-glucan products on a daily and/or regular basis (approximately 4 days/week) * Strong allergies/intolerance/sensitivities or food aversions to the foods involved in this study e.g. gluten * History of gastric ulcers, lung and respiratory diseases * History of severe neurological diseases or seizures * BMI greater than 40

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 4, 2026